This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Michael Kleerekoper, MD

JAMA. 1992;268(6):781-782.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

"Reduce hip fractures among people aged 65 and older sothat hospitalizations for this condition are no more than 607 per 100000. (Baseline: 714 per 100000 in 1988)"¹

This terse directive to the health care and lay communities alike acknowledges hip fractures as a major community health problem. It also emphasizes the significant potential for reduction in the incidence of these fractures, provided adequate attention is given to controllable risk factors. The challenge to all of us is to identify these factors, with an emphasis on those that are most cost-effective.

See also p 746.

Several studies have demonstrated that 5 to 10 years of estrogen replacement for perimenopausal women will reduce the incidence of hip and other osteoporotic fractures by as much as 50%.² While it is currently my practice to prescribe estrogen to all perimenopausal women in whom there is no contraindication, there is still considerable debate . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, Bone and Mineral Division, Henry Ford Hospital, Detroit, Mich.

Footnotes
Reprint requests to the Department of Medicine, Bone and Mineral Division, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, Ml 48202-2689 (Dr Kleerekoper).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?